Talazoparib for locally advanced and/or metastatic breast cancer with germline BRCA 1/2 positive mutation
NIHR HSRIC
Record ID 32016000409
English
Authors' objectives:
Breast cancer is the most common cancer in the UK. BRCA genes make proteins that help repair damaged DNA. Women with a BRCA gene mutation have a much higher risk of breast and other cancers. Most women who get breast cancer are over 50 years of age. However, people that have a breast cancer with BRCA gene mutation often get it at a younger age.
Talazoparib is a new treatment for breast cancer with germline BRCA mutation and that has spread locally or to other parts of the body. Some studies have suggested talazoparib may be helpful for people whose first chemotherapy treatment has failed and whose disease has spread and more studies are now aiming to show how well it works and that it is safe to use.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/talazoparib-for-locally-advanced-andor-metastatic-breast-cancer-with-germline-brca-12-positive-mutation/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Breast Neoplasms
- Poly(ADP-ribose) Polymerase Inhibitors
- Antineoplastic Agents
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.